Country: Canada
Language: English
Source: Health Canada
DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE); TIMOLOL (TIMOLOL MALEATE)
MINT PHARMACEUTICALS INC
S01ED51
TIMOLOL, COMBINATIONS
20MG; 5MG
SOLUTION
DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 20MG; TIMOLOL (TIMOLOL MALEATE) 5MG
OPHTHALMIC
10ML
Prescription
BETA-ADRENERGIC AGENTS
Active ingredient group (AIG) number: 0237301001; AHFS:
CANCELLED POST MARKET
2019-05-23
_Page 1 of 26_ PRODUCT MONOGRAPH PR MINT-DORZOLAMIDE/TIMOLOL Dorzolamide and timolol eye drops BP 2 0 mg/ml, 5 m g/ml (as dorzolamide hydrochloride and timolol maleate) Elevated Intraocular Pressure Therapy (Topical Carbonic Anhydrase Inhibitor and Topical Beta-Adrenergic Blocking Agent) MINT PHARMACEUTICALS INC. 1093 Meyerside Drive, Unit #1 Mississauga, Ontario L5T 1J6 DATE OF PREPARATION: 15 JULY 2015 SUBMISSION CONTROL NO: 185392 _Page 2 of 26_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS....................................................................................................7 DRUG INTERACTIONS ....................................................................................................8 DOSAGE AND ADMINISTRATION ................................................................................9 OVERDOSAGE ................................................................................................................10 ACTION AND CLINICAL PHARMACOLOGY ............................................................11 STORAGE AND STABILITY..........................................................................................13 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................13 PART II: SCIENTIFIC INFORMATION .................................................................................14 PHARMACEUTICAL INFORMATION...........................................................................14 CLINICAL TRIALS ................................ Read the complete document